TIDES Europe: Oligonucleotide and Peptide Therapeutics is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


Samuel Clarke
Director of R&D at Precision NanoSystems Inc


Dr. Samuel Clarke is an expert in the development of nanoparticles for biomedical applications and has more than 14 years experience in the field. Samuel is currently the Director of R&D at Precision NanoSystems Inc. where he is responsible for nanoparticle reagent and new application development for the NanoAssemblr platform. Samuel previously worked for STEMCELL Technologies Inc. where he invented, developed and commercialized multiple magnetic nanoparticle technologies for research and cell therapy applications. Samuel studied fluorescent quantum dot nanoparticles for diagnostic applications during his post-doc at the École Normale Supérieure and PhD at McGill University.

Samuel Clarke's Network

Agenda Sessions

  • Accelerating the Development of Transformative Nanomedicines with NxGen Microfluidics Technology

    , 12:30